The FDA has approved a supplemental new drug application for Rexulti for the treatment of agitation associated with dementia due to Alzheimer’s disease.According to a joint press release from Otsuka and Lundbeck, the approval makes Rexulti (brexpiprazole, Otsuka/Lundbeck) the first and only treatment approved in the United States for this common neuropsychiatric symptom of AD, which is